GET DAILY SIGNALSCompugen Ltd. (CGEN) Sees -15% Pullback Over Past Month as Catalyst Timeline Extends
Key Takeaways
- Compugen (CGEN) shares fell roughly 15% over the trailing 30 days, declining from about $2.33 to approximately $1.97.
- The pullback extended a broader multi-month slide, even as several analysts reiterated Buy ratings on the stock during October.
- The company's most anticipated catalyst — interim progression-free survival data from the MAIA-ovarian trial of COM701 — is not expected until the first quarter of 2027.
- Over the most recent quarter, the stock has retraced from a late-August peak, reflecting limited near-term clinical news flow and broader pressure on small-cap biotech.
- Partnerships with AstraZeneca (AZN) and Gilead Sciences (GILD) underpin the pipeline, with cash runway extending into 2029.
Company Background and Pipeline Focus
Compugen Ltd. is a clinical-stage cancer immunotherapy company headquartered in Holon, Israel, and listed on both Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN. The company uses Unigen, its AI-powered computational discovery platform, to identify novel drug targets and develop immunotherapies that activate the immune system against cancer.
Compugen's lead wholly owned asset is COM701, a potential first-in-class anti-PVRIG antibody being evaluated as a single-agent maintenance therapy in a blinded, randomized adaptive platform trial for patients with relapsed platinum-sensitive ovarian cancer. Its pipeline also includes rilvegostomig, a PD-1/TIGIT bispecific antibody developed by AstraZeneca (AZN) under an exclusive license, and GS-0321, a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead Sciences (GILD). Investors follow the stock for its AI-driven discovery platform, its partnered programs with major pharmaceutical companies, and its milestone and royalty potential. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Movement: 30 Days and the Quarter
Over the trailing 30 days, CGEN declined from approximately $2.33 to about $1.97, a drop of roughly 15%. The move was not a single-day event but a steady drift lower punctuated by short-lived bounces, consistent with a stock lacking imminent clinical catalysts.
The picture is similar over the most recent quarter. From roughly $2.26 in late July, the stock climbed to a quarterly high near $2.87 in late August before retracing. By late October it had fallen below $2.00, marking an intra-quarter decline of roughly 13% and leaving the stock near the lower end of its recent range.
Factors Behind the 30-Day Decline
The 30-day decline occurred even amid supportive analyst activity. During October, Oppenheimer, Stifel, and H.C. Wainwright each reiterated Buy ratings on Compugen with $4.00 price targets, and the stock carried a Strong Buy consensus with an average target above $4.00. These reiterations did not reverse the downtrend.
Several factors contributed to the negative price action. First, the company hosted a key opinion leader event on COM701 and the ovarian cancer treatment landscape in early October, but no new clinical data were released, leaving investors without a fresh catalyst. Second, the most important binary readout — interim median progression-free survival data from the MAIA-ovarian trial — is not anticipated until the first quarter of 2027, creating an extended period of limited news flow. Third, the stock appeared vulnerable to profit-taking after its late-August rally, and broader risk-off sentiment across small- and micro-cap biotechnology names added downward pressure. From what I see, this extended timeline is important because it leaves the shares exposed to sentiment shifts.
Quarterly Trend and Underlying Fundamentals
The broader quarterly trend reflects a familiar pattern for clinical-stage biotech: momentum-driven gains followed by a give-back in the absence of new data. Compugen shares rallied through late August to a peak near $2.87, buoyed in part by investor enthusiasm around AI-driven drug discovery and the company's Unigen platform. As that momentum faded and no new clinical readouts materialized, the stock drifted lower through September and into October.
Fundamentally, Compugen's underlying position remained unchanged during the period. Its partnered programs continued to advance, with AstraZeneca progressing rilvegostomig across multiple Phase 3 trials and Gilead advancing GS-0321 in Phase 1, while management reaffirmed an expected cash runway into 2029. The share-price weakness therefore reflected sentiment and positioning dynamics more than deterioration in the company's pipeline or financial foundation. I’m watching this closely as the partners provide the real leverage here.
Key Items on the Horizon for Investors
Investors should monitor several upcoming factors for Compugen. The company is scheduled to report third-quarter 2026 results on November 9, 2026, which will provide updates on cash position, R&D spending, and clinical progress. The pivotal catalyst remains the interim median progression-free survival analysis from the MAIA-ovarian trial of COM701, expected in the first quarter of 2027.
Beyond internal milestones, shareholder value will be influenced by partner activity: AstraZeneca's continued advancement of rilvegostomig across its Phase 3 program and Gilead's progress with GS-0321 carry milestone and royalty implications. Macroeconomic conditions, sector-wide appetite for speculative biotech, and any regulatory or geopolitical developments in Israel also remain relevant risks. These factors do not constitute financial advice, and outcomes are inherently uncertain.
Reviewing AI Trading Strategies for Context
In my ongoing review of market tools, I find value in stepping back from individual names to look at systematic approaches. Tickeron’s Trending AI Robots page offers a curated view of top-performing automated strategies across thousands of tickers. It highlights bots with different timeframes and risk profiles, which can provide useful perspective when evaluating how a stock like CGEN fits into broader trading patterns. This kind of cross-check helps ground the fundamental story in observable data without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGEN's RSI Oscillator recovers from oversold territory
The RSI Indicator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 37 of the 43 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CGEN turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
CGEN moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGEN crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.037). P/E Ratio (5.184) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (439.237).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement